|
Breast Carcinoma
|
0.430 |
GeneticVariation
|
disease |
BEFREE |
Genomic DNA samples from 227 women with early breast cancer were genotyped for NQO1 and NQO2 polymorphisms.
|
21946896 |
2011 |
|
Breast Carcinoma
|
0.430 |
Biomarker
|
disease |
BEFREE |
By exerting control on expression of specific cell cycle regulatory proteins in concomitance with suppression of cell proliferation, as well as the induction of NQO2, gamma-tocotrienol offers promise as an added chemopreventive and/or chemotherapeutic agent against breast cancer carcinogenesis.
|
20683025 |
2010 |
|
Breast Carcinoma
|
0.430 |
GeneticVariation
|
disease |
BEFREE |
Specifically, the susceptibility variants within NQO2 were notably associated with breast carcinomas with wild-type p53 (the most significant P-value: 3.3 x 10(-6)).
|
19351655 |
2009 |
|
Breast Carcinoma
|
0.430 |
Biomarker
|
disease |
HPO |
|
|
|
|
Breast Carcinoma
|
0.430 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Agranulocytosis
|
0.330 |
Biomarker
|
disease |
BEFREE |
The reduction of the clozapine nitrenium ion supports association studies showing that NQO2 is a genetic risk factor for clozapine-induced agranulocytosis.
|
29281794 |
2018 |
|
Agranulocytosis
|
0.330 |
Biomarker
|
disease |
BEFREE |
NQO2 1541AA (NRH quinone oxidoreductase 2; protects cells against oxidative metabolites) was present at a higher frequency in agranulocytosis patients compared with control (23% versus 7%, P=0.03), as was ABCB1 (ABC-transporter-B1; drug efflux transporter) 3435TT (32% versus 20%, P=0.05).
|
27168101 |
2017 |
|
Malignant neoplasm of breast
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Genomic DNA samples from 227 women with early breast cancer were genotyped for NQO1 and NQO2 polymorphisms.
|
21946896 |
2011 |
|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
BEFREE |
By exerting control on expression of specific cell cycle regulatory proteins in concomitance with suppression of cell proliferation, as well as the induction of NQO2, gamma-tocotrienol offers promise as an added chemopreventive and/or chemotherapeutic agent against breast cancer carcinogenesis.
|
20683025 |
2010 |
|
Malignant neoplasm of breast
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
In the first hospital-based study (n = 1604), we observed significant associations between the incidence of breast cancer and a 29 bp-insertion/deletion polymorphism (29 bp-I/D) and the rs2071002 (+237A>C) polymorphism, both of which are located within the NQO2 promoter region.
|
19351655 |
2009 |
|
Agranulocytosis
|
0.330 |
Biomarker
|
disease |
CTD_human |
Such a reduction in message suggests that the NQO2 gene may be involved in the development of clozapine-induced AGR.
|
14617031 |
2003 |
|
Agranulocytosis
|
0.330 |
Biomarker
|
disease |
BEFREE |
Such a reduction in message suggests that the NQO2 gene may be involved in the development of clozapine-induced AGR.
|
14617031 |
2003 |
|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
BEFREE |
Other behaviors related to anxiety (elevated plus maze), depression (forced swim), and schizophrenia (prepulse inhibition) were not affected in QR2-deficient mice.
|
20861374 |
2010 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
PSYGENET |
Other behaviors related to anxiety (elevated plus maze), depression (forced swim), and schizophrenia (prepulse inhibition) were not affected in QR2-deficient mice.
|
20861374 |
2010 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
LHGDN |
The present data suggest that individuals with the deletion of the 29 base pair sequence in the promoter region of the NQO2 gene may confer susceptibility to a certain form of schizophrenia.
|
14639047 |
2003 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
PSYGENET |
The present data suggest that individuals with the deletion of the 29 base pair sequence in the promoter region of the NQO2 gene may confer susceptibility to a certain form of schizophrenia.
|
14639047 |
2003 |
|
Schizophrenia
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
The present data suggest that individuals with the deletion of the 29 base pair sequence in the promoter region of the NQO2 gene may confer susceptibility to a certain form of schizophrenia.
|
14639047 |
2003 |
|
Psychotic Disorders
|
0.310 |
Biomarker
|
group |
PSYGENET |
This study suggests that the NQO2 gene polymorphism contributes to the aetiology of MAP-related psychosis in Japanese.
|
16191666 |
2005 |
|
Psychotic Disorders
|
0.310 |
GeneticVariation
|
group |
BEFREE |
This study suggests that the NQO2 gene polymorphism contributes to the aetiology of MAP-related psychosis in Japanese.
|
16191666 |
2005 |
|
Nonorganic psychosis
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
This study suggests that the NQO2 gene polymorphism contributes to the aetiology of MAP-related psychosis in Japanese.
|
16191666 |
2005 |
|
Nonorganic psychosis
|
0.310 |
Biomarker
|
disease |
PSYGENET |
This study suggests that the NQO2 gene polymorphism contributes to the aetiology of MAP-related psychosis in Japanese.
|
16191666 |
2005 |
|
Alcoholic Intoxication, Chronic
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Present data suggest that an insertion/deletion polymorphism in the promoter region of the NQO2 gene plays an important role in the pathogenesis of alcoholism and alcohol withdrawal symptoms.
|
12960511 |
2003 |
|
Alcoholic Intoxication, Chronic
|
0.310 |
PosttranslationalModification
|
disease |
BEFREE |
Present data suggest that an insertion/deletion polymorphism in the promoter region of the NQO2 gene plays an important role in the pathogenesis of alcoholism and alcohol withdrawal symptoms.
|
12960511 |
2003 |
|
Contact Dermatitis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genes specifically modulated in sensitized skins allow the detection of sensitizers in a reconstructed human skin model. Development of the SENS-IS assay.
|
25724174 |
2015 |